导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -14.02% | 4063/4773 |
| 近一周 | -4.75% | 5083/5462 |
| 近一月 | -2.13% | 1167/5421 |
| 近一季 | -2.18% | 1203/5209 |
| 近半年 | -17.87% | 4214/4920 |
| 近一年 | -16.37% | 3781/4366 |
| 近两年 | 13.88% | 2763/2954 |
| 近三年 | -13.34% | 2065/2253 |
| 成立以来 | 8.08% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.19% 2714/4961 |
-13.44% 4493/5312 |
- - |
- - |
| 2025 | 10.76% 2789/4813 |
-1.96% 2822/3635 |
3.29% 1063/4076 |
9.04% 3377/4524 |
0.31% 2066/4813 |
| 2024 | -3.95% 2226/3463 |
-2.00% 1304/2808 |
-5.94% 1823/3014 |
12.00% 2436/3129 |
-6.96% 2718/3463 |
| 2023 | -20.20% 1867/2656 |
-1.59% 1880/2280 |
-10.86% 2130/2385 |
-5.27% 1301/2515 |
-3.98% 835/2655 |
| 2022 | -12.95% 309/2207 |
-11.10% 479/1919 |
8.12% 391/2016 |
-11.29% 523/2113 |
2.09% 1041/2208 |
| 2021 | -0.50% 754/1822 |
-3.13% 767/1255 |
1.76% 1035/1330 |
-3.11% 613/1466 |
4.18% 359/1822 |
| 2020 | 47.79% 193/1250 |
13.79% 7/1028 |
10.64% 760/1067 |
11.87% 420/1164 |
4.93% 823/1184 |
| 2019 | 45.93% 142/1092 |
37.02% 78/754 |
0.78% 158/804 |
0.44% 517/850 |
5.20% 736/918 |
| 2018 | -18.42% 144/834 |
- - |
- - |
- - |
-8.57% 98/691 |
| 2017 | -0.37% 483/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.04% 370/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 前海开源中证大农业指数增强A VS. 长安沪深300非周期A(740101) |